A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)
PHASE1CompletedINTERVENTIONAL
Enrollment
53
Participants
Timeline
Start Date
April 30, 2004
Study Completion Date
September 30, 2004
Conditions
ContraceptionFemale Contraception
Interventions
DRUG
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00258076 - A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch) | Biotech Hunter | Biotech Hunter